NICE funding impacts treatment sequencing patterns in chronic myeloid leukaemia (CML)
- NICE recommendations determine access to tyrosine kinase inhibitors (TKIs)
- Median duration of treatment by line also decreased as more TKIs were recommended by NICE
- Promisingly, the study also found that the proportion of patients in major molecular response increased by line
Click here to read the abstract in the British Journal of Haematology (abstract number: BSH2020‐EP‐027)
SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.